Medartis completed its previously-announced acquisition of Nextremity Solutions (NSI). The move allows Medartis to further accelerate its U.S. extremities business. First products are slated for launch in early 2023, and will not have a material impact on the company's sales guidance in 2022.
The deal gives Medartis a dedicated lower extremity franchise in the U.S., and is expected to generate an additional $150 million in orthopedic product sales by 2028.
Nextremity's CEO, Rod K. Mayer, is appointed President of Medartis U.S. Manufacturing and R&D will be located at the former NSI headquarters, while supply chain, customer service and other commercial activities will be based at the current Medartis USA site in Pennsylvania.
Lisa C. Thompson, President North America for Medartis USA, has decided to resign following the successful reorganization of the U.S. business and the acquisition of NSI. She will support Rod K. Mayer during the transition phase.